Harvard Bioscience (HBIO) appears an attractive pick given a noticeable improvement in the company’s earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.
Analysts’ growing optimism on the earnings prospects of this medical instruments maker is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool — the Zacks Rank — is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive
externally-audited track record of outperformance
, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Harvard Bioscience, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate Revisions
The earnings estimate of $0.05 per share for the current quarter represents a change of 0% from the number reported a year ago.
The Zacks Consensus Estimate for Harvard Bioscience has increased 200% over the last 30 days, as one estimate has gone higher compared to no negative revisions.
Current-Year Estimate Revisions
For the full year, the company is expected to earn $0.28 per share, representing a year-over-year change of +75%.
In terms of estimate revisions, the trend for the current year also appears quite encouraging for Harvard Bioscience. Over the past month, one estimate has moved higher compared to no negative revisions, helping the consensus estimate increase 31.25%.
Favorable Zacks Rank
The promising estimate revisions have helped Harvard Bioscience earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
While strong estimate revisions for Harvard Bioscience have attracted decent investments and pushed the stock 5.3% higher over the past four weeks, further upside may still be left in the stock. So, you may consider adding it to your portfolio right away.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report